Key Takeaways PACB posted Q2 revenues of $39.8M, up 10.4% Y/Y, and an adjusted loss per share beating estimates.Consumables and service revenue grew, while adjusted gross margin rose 100 bps to 38% Y/Y in Q2.Global sales surged in APAC and EMEA; PACB also updated its 2025 revenue outlook to $155M-$165M.Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, delivered an adjusted loss per share of 13 cents in second-quarter 2025, narrower than the year-ago adjusted loss of 20 cents per sh ...